![](https://i.irp.nih.gov/pi/2003393685.jpg)
Amy Janes, Ph.D.
Investigator
Neuroimaging Research Branch, Cognitive and Pharmacological Neuroimaging Unit
NIDA
Research Topics
The long-term objective of our lab is to use neuroscience to guide the development of more personalized treatments for substance use disorders. This aim is supported by several shorter-term goals that include: 1) identifying neurobiological vulnerabilities for developing and maintaining addictive disorders; 2) determining how psychiatric disorders contribute to substance misuse; 3) determining the neurobiological impact of existing and developing treatments.
Biography
I received my Ph.D. in the Brain, Behavior, and Cognition division of Psychology at Boston University. While my thesis work focused on the molecular mechanisms of cocaine dependence in preclinical models, I transitioned to using clinical neuroimaging methods for my post-doctoral training at Harvard Medical School’s McLean Hospital. I remained at Harvard and McLean for over 14 years and most recently I was an Associate Professor of Psychiatry, Director of the Functional Integration of Addiction Research Lab, and Associate Director of the McLean T32 training program focused on research in Substance Use Disorders and Brain Imaging. I also held a joint appointment with Suffolk University to provide research training to pre-doctoral candidates attaining degrees in clinical psychology. I currently serve as President-Elect for the College on Problems of Drug Dependence and am a Tenure-Track Investigator at the NIDA-IRP.
Selected Publications
- Quam A, Biernacki K, Ross TJ, Salmeron BJ, Janes AC. Childhood Trauma, Emotional Awareness, and Neural Correlates of Long-Term Nicotine Smoking. JAMA Netw Open. 2024;7(1):e2351132.
- Korponay C, Janes AC, Frederick BB. Brain-wide functional connectivity artifactually inflates throughout functional magnetic resonance imaging scans. Nat Hum Behav. 2024.
- Murray L, Frederick BB, Janes AC. Data-driven connectivity profiles relate to smoking cessation outcomes. Neuropsychopharmacology. 2024;49(6):1007-1013.
- Ekhtiari H, Zare-Bidoky M, Sangchooli A, Janes AC, Kaufman MJ, Oliver JA, Prisciandaro JJ, Wüstenberg T, Anton RF, Bach P, Baldacchino A, Beck A, Bjork JM, Brewer J, Childress AR, Claus ED, Courtney KE, Ebrahimi M, Filbey FM, Ghahremani DG, Azbari PG, Goldstein RZ, Goudriaan AE, Grodin EN, Hamilton JP, Hanlon CA, Hassani-Abharian P, Heinz A, Joseph JE, Kiefer F, Zonoozi AK, Kober H, Kuplicki R, Li Q, London ED, McClernon J, Noori HR, Owens MM, Paulus MP, Perini I, Potenza M, Potvin S, Ray L, Schacht JP, Seo D, Sinha R, Smolka MN, Spanagel R, Steele VR, Stein EA, Steins-Loeber S, Tapert SF, Verdejo-Garcia A, Vollstädt-Klein S, Wetherill RR, Wilson SJ, Witkiewitz K, Yuan K, Zhang X, Zilverstand A. A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. Nat Protoc. 2022;17(3):567-595.
- Ward HB, Beermann A, Nawaz U, Halko MA, Janes AC, Moran LV, Brady RO Jr. Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence. Front Psychiatry. 2022;13:804055.
Related Scientific Focus Areas
Social and Behavioral Sciences
View additional Principal Investigators in Social and Behavioral Sciences
This page was last updated on Wednesday, August 7, 2024